Introduction
W hile tobacco use is widely known as a preventable cause of premature death, its causal association to blindness is relatively unknown by smokers. There is strong evidence that healthcare providers can positively affect tobacco cessation among their patients yet the voice of optometrists has been largely silent in the development of tobacco cessation practice guidelines and health promotion strategies such as social marketing campaigns and graphic warning labels. Our research group has begun to examine Canadian optometrists' key behaviors and attitudes toward patients who use tobacco. In this paper, we describe the level of Canadian smokers' knowledge of the association of smoking with blindness and the ideas that Canadian optometrists and senior optometry students have about blindness-related graphic warning labels.
Tobacco Use & Health Impacts
Optometrists routinely encounter patients who have, do, or will smoke cigarettes. A 2008 report 1 by the Propel Centre for Population Health Impact provides a compelling average profile of smoking among Canadians. An estimated 17.9% of Canadians over 14 years of age smoked cigarettes 1 , with higher rates among males (20%) than females (16%). Among daily smokers, who were the majority (75.4%), almost 15 cigarettes were smoked daily. Provincial rates of smoking varied from a low of 14 .7% in British Columbia to a high of 20.8% in Manitoba with only two provinces having rates below the national average (Ontario and British Columbia). The highest smoking prevalence (27%) existed among 20 to 24-year-olds and almost 19% of students in grades 5 to 9 had tried smoking. According to this report, two-thirds of smokers were seriously considering quitting in the next 6-months.
The leading causes of premature death causally linked to smoking are coronary artery disease, leading to myocardial infarctions and cerebrovascular accidents, lung cancer, and chronic obstructive pulmonary disease. 2 Public awareness of the negative consequences of smoking is generally high for these diseases; for example, studies in Canada, the United States, the United Kingdom, Australia and Singapore have reported that most surveyed respondents knew that smoking causes lung cancer (>90%), heart disease (>83%) and stroke (>70%). 3, 4, 5 levels between 31 and 37%. This limited awareness is a significant problem because smoking has been shown to cause several eye diseases through ischemic and oxidative mechanisms. 8 Smoking has been causally associated with age related macular degeneration [9] [10] [11] [12] [13] , nuclear and posterior subcapsular cataract [14] [15] [16] [17] [18] [19] , thyroid-associated ophthalmopathy [20] [21] [22] , optic neuropathies [23] [24] [25] and uveitis. 26, 27 While public knowledge of smoking-induced eye disease is relatively low, fear of blindness is not. A study 6 of British youth (16-18 years old) found that, in comparison with lung cancer, heart disease and stroke, blindness was the least known but most feared consequence of smoking cigarettes. Interestingly, some healthcare practitioners (e.g., pharmacists) are finding that linking smoking to blindness has been a successful part of their tobacco cessation advice. 28 The common occurrence of smoking, the limited public knowledge of smoking-associated eye disease, and the public's fear of vision loss all provide important incentives for optometrists to engage in patient education regarding tobacco prevention and cessation.
Health Practitioners Supporting Tobacco Prevention & Cessation
Addressing tobacco use in clinical practice is supported by an increasing recognition that tobacco use and dependence is a preventable cause of morbidity and mortality and healthcare providers can be effective facilitators of tobacco cessation among their patients. [29] [30] [31] [32] [33] [34] The U.S. Surgeon General's web-site provides clinical practice guidelines, entitled, Treating Tobacco Use and Dependence: 2008 Update. 35 This document was developed by stakeholders including those from medicine, nursing, dentistry, pharmacy, epidemiology, public health, and psychology. Unfortunately, optometry is notably missing as a stakeholder informant or as an identified user of the document. Optometry has also yet to be a stakeholder in the development of Health Canada's graphic warning labels for tobacco products. Graphic warning labels can be a useful tobacco prevention and cessation strategy, either on cigarette packages or posters. For example, they have been shown to increase the intentions of smokers to quit because of their heightened knowledge of the health effects of smoking. 36 Health Canada has had the same graphic warning labels on tobacco products for about ten years but it has not yet adopted an eye disease related warning label for smoking despite having one under consideration since 2006 (see the Tobacco Labeling Resource Centre for current and test Canadian warning labels: www. tobaccolabels.ca). In contrast, other countries [37] [38] have already adopted eye-related messages in their tobacco campaigns.
In this paper, we describe Canadian smokers' knowledge of the link between tobacco use and blindness as well as the recommendations of Canadian optometrists and senior optometry students about warning graphic labels specific to eye disease. The response options were: 'Yes', 'No', or 'Don't know'. The analysis in this paper is limited to respondents answering the blindness knowledge question for their first time. Since each wave (i.e., year) incorporates new participants to replenish those who have been lost to follow-up, there are new participants in each wave. Combining respondents from waves 3 to 7 (i.e., 2004 to 2008), provided a total weighted sample of 3,839 Canadian daily smokers. Response data were calculated provincially (by count and percentage of respondents); proportions were compared using 2-tailed z-tests with an alpha of 0.05 used for significance testing.
Methods

Perceptions of Eye-Related Graphic Warning Labels
Focus groups were conducted with optometry students and community optometrists. The study occurred in the Waterloo Region of southwestern Ontario, Canada in the summer of 2009.
Detailed descriptions of recruitment and sampling for this study have been published previously. 42, 43 The potential participant pool included 51 practicing optometrists and 30 fourth-year optometry students (60 additional fourth-year students were away on external clinical placements). Eighteen fourth-year optometry students (15 women, 3 men) were scheduled into three focus groups (S1, S2, and S3) and eleven optometrists (7 women, 4 men) were scheduled into two focus groups (O1 and O2). These optometrists had been practicing for approximately 20 years, on average, with an individual range from 5 to over 30 years. All but one had graduated from the local Doctor of Optometry program. The 29 participant identities were represented by numbers; for example, the seven members of student focus group S1 were numbered S1-1 to S1-7, and the six members of optometrist group O1 were numbered O1-1 to O1-6.
The multi-disciplinary research team, which drew from optometry, nursing, and psychology, developed a two-phase interview. The first phase addressed attitudes, practices and training regarding smoking behavior and smoking cessation referrals in optometric practice. The second phase focused on collecting reactions about the design content for possible tobacco product warning labels that included messages about tobacco use and eye health. Focus group respondents were given colour print-outs of ten different graphic warning label features designed for the current study by the research team. Some designs used images from graphic warning labels already used in Australia, New Zealand, and Iran. The ten warning labels addressed three categories: 1) 'Eye Disease' (four designs intended to communicate eye disease), 2) 'Vision Impact' (three designs aimed to communicate the experience of vision loss), and 3) 'Text Information' (three designs showed different text messages). The labels were designed to encourage discussion about what features or approaches the respondents felt were important. Table 1 shows the ten graphic label features discussed by the informants. Focus group facilitators (RDK & KM) were experienced in tobacco control research. A research assistant (VZ) made field notes during the focus group discussions, which were audio-recorded and later transcribed verbatim.
We followed an inductive qualitative framework approach 44 where data analysis informs theory. Consistent with a framework approach, reading the focus group transcripts allowed the members of the research team to familiarize themselves with the data. Next, the team identified key issues, themes and concepts by which the data could be further examined. The team identified five broad themes to examine: current practices, rationalizations, barriers, opportunities and graphic label recommendations. Data excerpts that fit with the identified themes were indexed in the transcripts and then rearranged into thematic charts (a few exemplar excerpts are included in this paper). Finally, the thematic charts were examined with the goal of finding associations and explanations for the findings; a process referred to by Bryman and Burgess 44 as 'mapping and interpretation'. Analysis of the first four themes is reported elsewhere [42] [43] ; theme five, 'graphic label recommendations', is reported herein.
Results & Discussion
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Perceptions of Eye-Related Graphic Warning Labels
Analysis of the focus group discussions regarding the graphic warning labels revealed two sub-themes: 1) Accurately Linking Smoking and Blindness, and 2) Framing Desirable Messages. Respondents thought that both the views of optometrists and the public should be considered ultimately in designing a suitable eye-focused graphic warning label. Both the optometrists and senior optometry students placed high importance on graphic warning labels that accurately linked smoking and blindness. Respondents felt that these labels should depict either common eye diseases associated with smoking (e.g., age-related macular degeneration or cataract) or communicate the experience of vision loss expected from these diseases (e.g., the impact of central vision loss with ARMD). Table 3 shows the most preferred graphic warning label features in the categories of 'Eye Disease', 'Vision Impact' and 'Text Information'. It was very important to respondents that the graphic image be a plausible risk of smoking; for example, respondents objected to one 'Eye Disease Graphic' that appeared more illustrative of eye trauma than smoking. Optometrist O1-1, highlighted this concern, saying, "I think a lot of people smoking are going to go, 'Yeah, right, like that's going to happen to my eye if I smoke! Like give me a break!' ". Numerous respondents voiced a concern that a majority of the public do not know enough about eyes, eye disease and the links to smoking; thus the graphic label must seem a plausible consequence of smoking despite most viewers having a limited knowledge of the eye and eye disease. The respondents felt that most people could recognize an obviously diseased lung or heart but few would recognize a photo of age-related macular degeneration or cataract. As O1-4 noted after looking at the four 'Eye Disease Graphics', "You know when a lay person looks at these pictures, half of the time they won't recognize them". In part, because of this lack of knowledge, more of the respondents preferred graphic warning labels that performance and fertility (i.e., ability of female rats to become pregnant). However, these doses were highly toxic and had significant toxic effects on the pregnancies, and the survival and development of the offspring. Maternal toxicity, possible occurrence of abnormalities and growth retardation started at 10 times the Alrex ® clinical dose.
Neurologic
Disturbances and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis can occur with systemic exposure to corticosteroids. However, given the very low systemic exposure to loteprednol etabonate when using Alrex ® as directed, these possible effects are not likely.
Endocrine and Metabolism
Glucocorticoids, mostly when systemic exposure occurs, decrease the hypoglycemic activity of insulin and oral hypoglycemics, so that a change in dose of the antidiabetic drugs may be necessitated. In high doses, glucocorticoids also decrease the response to somatotropin. The usual doses of mineralocorticoids and large doses of some glucocorticoids cause hypokalemia and may exaggerate the hypokalemic effects of thiazides and high-ceiling diuretics. In combination with amphotericin-B, they also may cause hypokalemia. Glucocorticoids appear to enhance the ulcerogenic effects of non-steroidal anti-inflammatory drugs. They decrease the plasma levels of salicylates, and salicylism may occur on discontinuing steroids. Glucocorticoids may increase or decrease the effects of prothrombopenic anticoagulants. Estrogens, phenobarbital, phenytoin and rifampin increase the metabolic clearance of adrenal steroids and hence necessitate dose adjustments. However, given the very low systemic exposure to loteprednol etabonate when using Alrex ® as directed, these possible effects are not likely.
Immune
Cortisol and the synthetic analogs of cortisol have the capacity to prevent or suppress the development of the local heat, redness, swelling, and tenderness by which inflammation is recognized. At the microscopic level, they inhibit not only the early phenomena of the inflammatory process (edema, fibrin deposition, capillary dilation, migration of leukocytes into the inflamed area, and phagocytic activity) but also the later manifestations, such as capillary proliferation, fibroblast proliferation, deposition of collagen, and, still later, cicatrisation.
Clinical Trial Adverse Drug Reactions
Possibly or probably related adverse events from two Phase III studies are listed below:
One patient in the Alrex ® group and one patient in the placebo group experienced increases in IOP of ≥10 mm Hg. Among these, one in each group had an IOP increase of ≥15 mm Hg, reaching IOP values over 30 mm Hg. In both studies, there were more patients with IOP increases of 6 to 9 mm Hg in the Alrex ® group than in the placebo group (see table below). In study A, among the patients with IOP increases of 6 to 9 mm Hg, four reached an IOP value of 22 to 23 mm Hg, and one patient reached 29 mm Hg and was discontinued (clinically significant increase in IOP). All these five patients were from the Alrex ® groups.
Incidence of IOP increases of 6 to 9 mm Hg from baseline (number of patients and percentages)
Due to the sample size for each arm of the two phase III studies in SAC, all events captured are greater than 1% of n. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE
showed smoking-induced impacts on vision rather than the related ocular pathology. As one optometry student noted looking at the preferred 'Vision Impact Graphic' (Table 2) , "You're putting yourself in those eyes and saying, 'Oh, my God, I won't be able to see my loved ones'. And that hits home" (S3-4). Respondents also preferred text that included direct language, stats and incentives about reducing risk. As S3-2 argued, "I think if you want people to stop smoking you should provide them with the facts." Respondents also placed a high priority on framing desirable messages. Interestingly, the optometrists and optometry students believed that graphic warning labels are largely intended to motivate quitting through scare tactics but they would rather motivate quitting through education and empowerment. For example, it should be important to those who smoke to know how much their risk of blindness is lowered by tobacco cessation. Numerous respondents indicated that different strategies were needed for youth (e.g., unable to drive a car) than seniors (e.g., unable to see grandchildren). Several respondents also felt that eye diseases seen predominantly in seniors (e.g., AMD, cataract) would not motivate youth to avoid or quit smoking and if there was an age cohort where scare tactics might be successful, it was the youth. As O2-4 noted, "Your older group would appreciate macular degeneration but not if you're targeting the young ones… So, I think you need to have multiple messages".
While optometrists may not have specific training in social judgment, message framing, and statistical heuristics deployed by health psychologists and public health experts, these focus group data show that optometrists have important ideas to contribute to this discussion. Many of the informants in this study supported the idea of having posters and other promotional materials in their practices, provided they judged the materials to be accurate, sensitive and suitable. Thus, if the tobacco control community begins to use eye health related messaging, it will be important to develop messages with which eye care professionals feel comfortable.
Implications
Consistent with studies of other countries, knowledge is low among Canadian smokers about the causal association of smoking and blindness. Further research is needed to identify the reasons for this limited knowledge; however, with, on average, only 1 in 7 Canadian smokers knowing about this link, there is a clear opportunity for increased patient education by optometrists, other healthcare practitioners and public health workers. Knowing both about the age at which smoking often starts 46 and its addictive qualities, optometrists should be routinely incorporating interview questions about smoking, starting with patients over 10 years of age. Tobacco use assessment should include the onset, the amount (e.g., number of cigarettes per day) and the type of tobacco use (e.g., smoking, chew, snuff), the interest in quitting and past quit attempts. Tobacco dependence intervention by optometrists can help reduce the health consequences incurred with tobacco use. Toward this end, optometrists can contact their local public health department to learn more about tobacco cessation programs in their area and incorporate some of this information into their patient counseling, including contacts for the national and provincial quit lines. 2 Like other healthcare providers, optometrists can facilitate higher quit rates among smokers who learn about its health effects and cessation strategies. The 29 optometry participants in this study were clear in their conviction that optometrists should be at the table, helping to design effective educational tools linking smoking to blindness. The findings of this preliminary study may help inform the development of tobacco prevention and cessation tools and materials ultimately used by optometrists in their practices. Optometrists seem to want more of their patients to see the causal association of smoking and blindness, the ocular and systemic benefits of tobacco cessation, and informative, motivating eye health messages about tobacco use. 
Acknowledgements
